Objective assessment of compliance with psoriasis treatment.
OBJECTIVE
To assess patient compliance with psoriasis treatment.


METHODS
Open prospective study. Patients with psoriasis were examined and completed a brief medical and social history, a compliance assessment sheet, and the Dermatology Life Quality Index (DLQI). Patients were reexamined at 3 months, and their actual treatment use was assessed and compared with the expected use. Medication adherence was assessed by direct questioning.


METHODS
Dermatology outpatient clinic.


METHODS
Two hundred ninety-four patients fulfilled the inclusion criteria, and 201 completed the study.


METHODS
Adherence with topical and oral therapies, using objective and self-reporting methods and description of factors affecting compliance.


RESULTS
The overall mean +/- SD medication adherence was 60.6% +/- 33.0% (range, 0%-169%). The mean +/- SD DLQI in the study was 17.4 +/- 8.9 (range, 0-30). There was a highly significant negative correlation (r = -0.92) between these variables. Being female, married, employed, and not paying for prescriptions were characteristics associated with increased medication adherence and a lower DLQI. Medication adherence was greater for topical or combined therapy, for once-daily treatment, and for first-time use of treatment. Adverse effects reduced compliance. The major reasons for missing treatment were drinking alcohol, being fed up, forgetfulness, and being too busy. Patients with facial disease and with more extensive disease had lower medication adherence.


CONCLUSIONS
A range of disease-related and social factors may affect compliance with psoriasis treatment. The inversely proportional relationship between DLQI and medication adherence reflects the interaction of physical and psychological factors, as well as perceived treatment failure.
Zaghloul
Sameh Said
SS
Department of Dermatology, The General Infirmary at Leeds, England. samehzaghloul@yahoo.co.uk
Goodfield
Mark Jeremy David
MJ
D000284:Administration, Oral; D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D016001:Confidence Intervals; D003879:Dermatologic Agents / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance / Q000706:statistics & numerical data*; D011336:Probability; D011379:Prognosis; D011446:Prospective Studies; D011565:Psoriasis / Q000175:diagnosis*; D011788:Quality of Life; D018570:Risk Assessment; D012720:Severity of Illness Index; D012737:Sex Factors; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
D003879:Dermatologic Agents